Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Archemix Outlicenses Aptamers To Ophthotech

This article was originally published in The Pink Sheet Daily

Executive Summary

Ophthotech, a new firm formed by several ex-Eyetech managers, will develop anti-C5 compounds as candidates to treat age-related macular degeneration.

You may also be interested in...



Archemix Reduces Aperture to Pursue Orphan Diseases

Archemix has consolidated IP in the aptamer space and enjoyed success in partnering its technology. But public markets have frozen the company out and it is now focusing on orphan hematologic diseases. The move should help the company conserve cash while creating earlier out-licensing opportunities as Archemix transitions into later-stage development.

Ophthotech Will Take Biogen/PDL Drug Volociximab Into The Clinic For AMD

Alpha 5 beta 1 integrin antagonist will move into the clinic “shortly,” CEO Patel tells “The Pink Sheet” DAILY.

Ophthotech Will Take Biogen/PDL Drug Volociximab Into The Clinic For AMD

Alpha 5 beta 1 integrin antagonist will move into the clinic “shortly,” CEO Patel tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

PS066438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel